The global indoleamine 2,3 dioxygenase 1 market is anticipated to grow at a substantial CAGR during the forecast period. Immunotherapy's recent application in clinical oncology has changed the way we treat advanced human tumors. Immunotherapeutic drugs targeting the CTLA4 and PD-1/PD-L1 axis are currently available to treat a range of malignancies. However, to further improve patient outcomes with these medications, a unique treatment approach is required. indoleamine 2,3-dioxygenase 1 (IDO1) is a rate-limiting enzyme in the peripheral tissue metabolism of the essential amino acid tryptophan.
Browse the full report description of “Global Indoleamine 2,3 Dioxygenase 1 Market Size, Share, and Trends Analysis Report by Type (BMS-986205, Dcellvax, Epacadostat, F-001287, Galanal, and Others), and by Application (Alopecia, Cervical Cancer, Gastric Cancer, Glioma, and Others) Forecast Period (2022-2028)” at https://www.omrglobal.com/industry-reports/indoleamine-2-3-dioxygenase-1-market
In human cancer cells, IDO1 is overexpressed, suppressing effector T cell function while promoting regulatory T cells (Tregs). In different kinds of human cancer, IDO1 overexpression is linked to poor patient survival. These data suggest that IDO1 is a viable target in the field of immuno-oncology, with the potential to improve therapy outcomes. In the last few years, many orally accessible IDO1 inhibitors, notably Epacadostat, have entered human clinical trials with no notable safety concerns. PD-1 inhibitors in combination appear to be more effective than PD-1 inhibitors alone, notwithstanding the lack of objective response in single-agent trials. In the recent phase III ECHO 301 study in melanoma, the combination of Epacadostat with Pembrolizumab did not show a better outcome than Pembrolizumab alone. Other phases III trials involving IDO1 inhibitors were halted as a result of this.
Market Coverage
• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
o By Type
o By Application
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
• Competitive Landscape- including Bristol-Myers Squibb, Merck KGaA, BirchBioMed Inc., Genentech Inc., F. Hoffmann-La Roche Ltd., and others.
Key questions addressed by the report
• What is the market growth rate?
• That segment and region dominate the market in the base year?
• That segment and region will project the fastest growth in the market?
• How does COVID-19 impact the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?
Global Indoleamine 2,3 Dioxygenase 1 Market Report by Segment
By Type
By Application
Global Indoleamine 2,3 Dioxygenase 1 Market Report Segment by Region
North America
• US
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East and Africa
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/indoleamine-2-3-dioxygenase-1-market